DPP4 and type 2 diabetes mellitus: A meta analysis was performed by Monami et al. (2011) on all trials that enrolled T2DM patients that received DPP-4 inhibitors for at least 24 weeks: fractures were reported only as adverse effects and probably not all types of fractures were described carefully; nevertheless, collected data revealed that the total number of fractures was lower in patients treated with DPP-4 inhibitors, suggesting a potential protective effect on bone of this class of drugs.